Physician Scientist
Department of Immunology
Roswell Park Cancer Institute

Assistant Professor
Lymphoma/Myeloma Service
Department of Medicine, Roswell Park Cancer Institute

Francisco J. Hernandez-Ilizaliturri, MD, joined the staff of Roswell Park Cancer Institute in 2003, as an Assistant Professor, Department of Medicine, and Physician Scientist in the Department of Immunology.

Dr. Hernandez-Ilizaliturri earned his medical degree from the Instituto Tecnologico y de Estudio Superiores de Monterrey, Mexico, in 1995. He completed residency training in Internal Medicine at the State University of New York at Buffalo School of Medicine and Biomedical Sciences in 1999 and fellowship training in the departments of Medicine and Immunology at RPCI in 2002. He is licensed by New York State and is board-certified in Medical Oncology and Internal Medicine by the American Board of Internal Medicine.

Dr. Hernandez-Ilizaliturri's research interests include the study the mechanisms associated with resistance to monoclonal antibodies in lymphoma patients and developing new strategies to enhance the activity of therapies such as Rituximab and other monoclonal antibodies. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, American Medical Association and the American College of Physicians.

Dr. Hernandez-Ilizaliturri has authored or co-authored more than 25 journal publications, book chapters and abstracts.

1. Hernandez-Ilizaliturri F.J., Jupudy V., Oflazoglu E., Huberman A., Ostberg J., Repasky E.A., and Czuczman M.S. Neutrophils Contribute to the Biological anti-tumor activity of Rituximab in a Non-Hodgkin’s Lymphoma Severe Combined Immunodeficiency (SCID) Mouse Model. Clinical Cancer Research 2003: 9; 5866-5873.
2. Hernandez-Ilizaliturri F.J., Connolly G., Cipolla D., and Ramnath N. Thymic Carcinoma (TCA): Clinico-Pathological Factors: 30 Years Roswell Park Cancer Institute Experience. Am J Clin Oncol 2004; 27: 68–72.
3. Hernandez-Ilizaliturri F.J., Gada P., Czuczman M.S. Emerging humanized monoclonal antibodies against Non-Hodgkin’s Lymphoma. Cancer Conference Highlights: ASH Meeting 2002.
4. Ramnath N., Hernandez F.J., and Bepler G. Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer - Will the Answer Lie in Targeted Chemotherapy? Oncology Spectrums 2002; 3: 27-34
5. Ramnath N., Hernandez F.J., Tan D., Huberman J.A., Natarajan N., Beck A.F., Hyland A., Todorov I., Brooks J.S.J., and Bepler G. MCM2 is an Independent Predictor Factor of Survival in Patients with Non-Small Cell Lung Cancer. Journal of Clinical Oncology 19:4259-4266, November 2001.
6. Ramanarayanan1 R, Hernandez-Ilizaliturri F.J., Chanan-Khan A., and Czuczman M.S. Pro-apoptotic therapy with the oligonucleotide Genasense™ (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumor activity of rituximab. Manuscript submitted for publication to Blood.